| Trustees | Professor Michael | Professor Michael | Milward | President | 2023 | 2023 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dr Ra/an Nansi |
President | 2022 | ||||||||
| Professor Mark | Ide | Immediate | Past President | Resigned | 31 December 2022 | |||||
| Professor Wendy Turner | Honorary | Secretary | ||||||||
| Dr lan Dunn | Honorary | Treasurer | ||||||||
| Professor Philip |
Preshaw | President | Elect 2024 | Appointed | 1 January 2023 | |||||
| Professor Nicola West | President | Elect 2025 | ||||||||
| Professor Francis Hughes | Senior Vice | President | Resigned | 31 December 2022 | ||||||
| Professor Gerry | Linden | Senior Vice | President | Appointed | 1 January 2023 | |||||
| Dr Alexander Pollard |
Honorary | Editor | ||||||||
| Dr Viren Vithlani | Commercial | Liaison Officer | ||||||||
| Charity | number | 265815 | ||||||||
| Princl pa | I address | P0 Box261 | ||||||||
| Liverpool | ||||||||||
| L25 6WP | ||||||||||
| Independent | examiner | Alison Whalley | FCA | |||||||
| Azets | ||||||||||
| Carlton House | ||||||||||
| Bradford | ||||||||||
| BD1 4NS | ||||||||||
| Bankers | CAF Bank Ltd | |||||||||
| 25 Kings Hill Avenue |
||||||||||
| Kings Hill |
||||||||||
| West Mailling | ||||||||||
| Kent | ||||||||||
| ME194JQ | ||||||||||
| Bank ofScotland | ||||||||||
| 33 Old Broad Street | ||||||||||
| London | ||||||||||
| BX2 1LB |
| Page | |||
|---|---|---|---|
| Trustees report |
1-9 | ||
| Independent examiner's |
report | 10 | |
| Statement of financial |
activities | ||
| Balance sheet | 12 | ||
| Notes to the accounts | 13-23 |
| PRIZE | Award | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Audit award | |||||||||||
| F500 | |||||||||||
| No award | |||||||||||
| Sir Wilfred Fish | Research | Prize | |||||||||
| Vitor Neves | E1,000 | ||||||||||
| "Glucose metabolism medicine. " |
modulation | in periodontal | disease prevention | as a form ofpreventive | |||||||
| S stematic | Review Prize | ||||||||||
| Varkha Rattu |
E1,000 | ||||||||||
| "Prevalence | ofstable | and | successfully | treated | periodontitis | subjects and incidence ofsubsequent " |
|||||
| tooth loss within | supportive | periodontal | care: A systematic | review and meta-analyses. | |||||||
| BSPClinical | Fellowshl | award | Up to E4,000 | ||||||||
| Hong Jin Tan | per award | ||||||||||
| Frank Ashle | Under | raduate | Prize | ||||||||
| E500 | |||||||||||
| Kate McNelly | |||||||||||
| BSPResearch Grant | Up to F5,000 | ||||||||||
| Joshua Jackson | per award | ||||||||||
| Poster Prize | |||||||||||
| Clinical: | |||||||||||
| Chaitanya Joshi |
f500 each | ||||||||||
| Research: | |||||||||||
| Annabel Simpson |
| Date | Type of Event |
Title | Presenter |
|---|---|---|---|
| Time to take periodontitis seriously: economic &societal |
|||
| 20 Jan | Webinar | costs and how to implement the steps ofcare in real |
Prof lain Chapple |
| world NHS practice | |||
| Avoidance of Doubt - the S3guidelines and phased |
|||
| 10Feb | Webinar | treatment approach to periodontal care within the NHS |
Dr Shazad Saleem |
| dental contract | |||
| 10 Mar | Webinar | Approaching/implementing behaviour change in treating periodontal disease in practice |
Dr Christoph Ramseier |
| 26 Apr | Webinar | Management of peri-implantitis a pragmatic approach |
Prof Andreas Stavropoulos |
| 17 May | Webinar | Pre-prosthetic surgery - Enabling optimal restorations |
Prof Moritz Kebschull |
| Minimally invasive non-surgical periodontal therapy |
|||
| 9 Jun | Webinar | practical approaches and protocols to ultrasonic |
Dr Devan Raindi |
| debridement | |||
| 22nd Jun | Masterclass | Peri-Implantitis Masterclass —Diagnosis and Treatment Modalities |
Prof Nikos Donos |
| 12Jul | Webinar | Instrumentation selection and advanced techniques for sub gingival PMPR |
Ms Claire McCarthy |
| 13-15hOct | Conference | BSPConference 2022 | Dr Rajah Nansi |
| 1 Nov | Webinar | Supportive Periodontal Care —Practical implementation ofstep 4 of the S3guidelines |
Dr Viren Vithlani |
| 16 Nov | Webinar | The Bernese Concept for the Treatment of Single and Multiple Mandibular Recessions |
Prof Anton Sculean |
| Unrestricted | Restricted | Total | Unrestricted | Restricted | Total | ||
|---|---|---|---|---|---|---|---|
| funds | funds | funds | funds | ||||
| 2022 | 2022 | 2021 | 2021 | 2021 | |||
| Notes | 6 | 6 | f | 8 | 6 | ||
| Income from: | |||||||
| Donations and legacies |
3 | 1,000 | 1,000 | 1,000 | 6,000 | 7,000 | |
| Charitable activities |
4 | 366,919 | 85,000 | 451,919 | 394,626 | 50,000 | 444,626 |
| Investments | 5 | 3,361 | 3,361 | 861 | 861 | ||
| Total income | 371,280 | 85,000 | 456,280 | 396,487 | 56,000 | 452,487 | |
| ~E«dlt | |||||||
| Charitable activities |
6 | 319,305 | 32,587 | 351,892 | 324,490 | 33,737 | 358,227 |
| Net Income for the year/ | |||||||
| Net movement ln funds |
51,975 | 52,413 | 104,388 | 71,997 | 22,263 | 94,260 | |
| Fund balances at 1 | |||||||
| January 2022 | 561,065 | 75,895 | 636,960 | 489,068 | 53,632 | 542,700 | |
| Fund balances at 31 | |||||||
| December 2022 | 613,040 | 128,308 | 741,348 | 561,065 | 75,895 | 636,960 |
| 2022 | 2021 | |||||||
|---|---|---|---|---|---|---|---|---|
| Notes | 6 | 8 | ||||||
| Fixed assets | ||||||||
| Tangible assets | 705 | |||||||
| Current assets | ||||||||
| Debtors | 12 | 35,236 | 28,048 | |||||
| Cash at bank and | in | hand | 736,832 | 660,528 | ||||
| 772,068 | 688,576 | |||||||
| Creditors: amounts | falling | due within | ||||||
| one year | 13 | (31,425) | (51,616) | |||||
| Net current assets | 740,643 | 636,960 | ||||||
| Total assets less | current | liabilities | 741,348 | 636,960 | ||||
| Income funds | ||||||||
| Restricted funds | 15 | 128,308 | 75,895 | |||||
| Unrestricted funds |
||||||||
| Designated funds |
16 | 371,920 | 371,825 | |||||
| General unrestricted |
funds | 241,120 | 189,240 | |||||
| 613,040 | 561,065 | |||||||
| 741,348 | 636,960 |
| Charitable | Charitable | ||
|---|---|---|---|
| Income | Income | ||
| 2022 | 2021 | ||
| 8 | 6 | ||
| Subscriptions | 201,535 | 195,617 | |
| Partnership | agreements | 85,OOO | 50,000 |
| Conferences | 144,064 | 189,425 | |
| Educational | courses and webinars | 18,000 | 6,530 |
| Leaflet sales | 3,320 | 3,054 | |
| 451,919 | 444,626 | ||
| Analysis by fund |
|||
| Unrestricted | funds | 366,919 | 394,626 |
| Restricted | funds | 85,000 | 50,000 |
| 451,919 | 444,626 |
| Unrestricted | Unrestricted | ||
|---|---|---|---|
| funds | funds | ||
| 2022 | 2021 | ||
| 6 | 6 | ||
| Interest | receivable | 3,361 | 861 |
| 2022 | 2021 | ||
|---|---|---|---|
| 6 | 6 | ||
| Journal - paper | 9,512 | 10,729 | |
| Journal - electronic |
37,519 | 39,085 | |
| Conference costs | 89,143 | 149,464 | |
| Event management | fees | 32,817 | 23,907 |
| Awards and prizes |
12,331 | 10,682 | |
| Educational initiative |
26,265 | 33,737 | |
| Educational courses |
and webinars | 19,793 | 9,042 |
| BSPEvents/Non BSPEvents |
7,314 | ||
| Donations and sponsorship |
1,030 | ||
| 235,724 | 276,646 | ||
| Share ofsupport costs (see note 7) | 105,600 | 76,50e | |
| Share of governance | costs (see note 7) | 10,568 | 5,073 |
| 351,892 | 358,227 | ||
| Analysis by fund |
|||
| Unrestricted funds |
319,305 | 324,490 | |
| Restricted funds |
32,587 | 33,737 | |
| 351,892 | 358,227 |
| 7 | Supportcosts | |||||||
|---|---|---|---|---|---|---|---|---|
| Support | Governance | 2022 | Support | Governance | 2021 | |||
| costs | costs | costs | costs | |||||
| f | f | 6 | f | |||||
| Depreciation | 503 | 503 | ||||||
| Legal fees | 1,056 | 1,056 | ||||||
| Admin travel |
268 | 268 | 110 | 110 | ||||
| Business Management | ||||||||
| fees | 54,402 | 54,402 | 44,358 | 44,358 | ||||
| Office costs | 13,939 | 13,939 | 9,347 | 9,347 | ||||
| Insurance | 668 | 668 | 610 | 610 | ||||
| Sundry | 562 | 562 | 1,001 | 1,001 | ||||
| Irrecoverable VAT |
25,209 | 25,209 | 13,583 | 13,583 | ||||
| Computer and |
website | 2,801 | 2,801 | 2,012 | 2,012 | |||
| Worldpay and |
Bank | |||||||
| charges | 5,343 | 5,343 | 2,178 | 2,178 | ||||
| Accountancy | 849 | 849 | 3,309 | 3,309 | ||||
| Cost oftrustees | meetings | 525 | 525 | 41 | 41 | |||
| Independent examination |
4,500 | 4,500 | 4,500 | 4,500 | ||||
| Indemnity insurance |
881 | 881 | 456 | 456 | ||||
| Trustees and council | ||||||||
| members expenses |
4,662 | 4,662 | 76 | 76 | ||||
| 105,600 | 10,568 | 116,168 | 76,508 | 5,073 | 81,581 | |||
| Analysed between |
||||||||
| Charitable activities |
105,600 | 10,568 | 116,168 | 76,508 | 5,073 | 81,581 |
| 11 | Tangible fixed assets | Tangible fixed assets | Tangible fixed assets | |||
|---|---|---|---|---|---|---|
| Fixtures and fittings | ||||||
| 6 | ||||||
| Cost | ||||||
| At 1 January | 2022 | 4,250 | ||||
| Additions | 1,208 | |||||
| At 31 December 2022 | 5,458 | |||||
| Depreciation | and Impairment | |||||
| At 1 January | 2022 | 4,250 | ||||
| Depreciation | charged | in the year | 503 | |||
| At 31 December 2022 | 4,753 | |||||
| Carrying amount |
||||||
| At 31 December 2022 | 705 | |||||
| 12 | Debtors | |||||
| 2022 | 2021 | |||||
| Amounts falling due |
within one year: | 8 | 8 | |||
| Trade debtors | 24,000 | |||||
| Other debtors | 1,817 | 1,608 | ||||
| Prepayments | and accrued income | 33,419 | 2,440 | |||
| 35,236 | 28,048 | |||||
| 13 | Creditors: amounts | falling due within one year | ||||
| 2022 | 2021 | |||||
| Notes | 6 | f | ||||
| Deferred income | 14 | 21,560 | 33,027 | |||
| Trade creditors | 5,115 | 5,255 | ||||
| Accruals | 4,750 | 13,334 | ||||
| 31,425 | 51,616 |
| 2022 | 2021 | |||||||
|---|---|---|---|---|---|---|---|---|
| E | E | |||||||
| Other deferred | income | 21,560 | 33,027 | |||||
| Deferred | income | is included | in the financial | statements | as follows: | |||
| 2022 | 2021 | |||||||
| E | E | |||||||
| Brought | forward | 33,027 | 178,135 | |||||
| Amount | released | to income | (33,027) | (175,316) | ||||
| Amount | deferred | in year | 21,560 | 33,027 | ||||
| Refunded | (2,819) | |||||||
| Carried | forward | 21,560 | 33,027 |
| Movement | in funds | Movement | in funds | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Balance at | Incoming | Resources | Balance at | Incoming | Resources | Balance at | ||||
| 1 | January | 2021 | resources | expended1 | January | 2022 | resources | expended | 31 December | |
| 2022 | ||||||||||
| E | F | E | E | E | ||||||
| Partnership | ||||||||||
| Agreements | 53,632 | 50,000 | (33,737) | 69,895 | 85,000 | (32,337) | 122,558 | |||
| Patient | ||||||||||
| Forum | 6,000 | 6,000 | (250) | 5,750 | ||||||
| 53,632 | 56,000 | (33,737) | 75,895 | 85,000 | (32,587) | 128,308 |
| Balance at | Transfers | Balance at | Transfers | Balance at | ||
|---|---|---|---|---|---|---|
| 1 January 2021 |
1 January 2022 |
31 December | ||||
| 2022 | ||||||
| E | E | |||||
| Contingency | Fund | 141,670 | 284 | 141,954 | 95 | 142,049 |
| EP8 2015 Legacy | 175,000 | 175,000 | 175,000 | |||
| EP9 2018 Legacy | 54,871 | 54,871 | 54,871 | |||
| 371,541 | 284 | 371,825 | 95 | 371,920 |
| Funds | |||||||
|---|---|---|---|---|---|---|---|
| Balance at1 | Income | Expenditure | Transfers | Balance at 31 | |||
| January 2022 |
December | ||||||
| 2022 | |||||||
| E | E | E | E | E | |||
| Restricted | funds | 75,895 | 85,000 | (32,587) | 128,308 | ||
| Designated | funds | 371,825 | 95 | 371,920 | |||
| General | funds | 189,240 | 371,280 | (319,305) | (95) | 241,120 | |
| 636,960 | 456,280 | (351,892) | 741,348 | ||||
| Funds | prior year | ||||||
| Balance at 1 | Income | Expenditure | Transfers | Balance at 31 | |||
| January 2021 |
December | ||||||
| 2021 | |||||||
| E | E | E | E | E | |||
| Restricted | funds | 53,632 | 56,000 | (33,737) | 75,895 | ||
| Designated | funds | 371,541 | 284 | 371,825 | |||
| General | funds | 117,527 | 396,487 | (324,490) | (284) | 189,240 | |
| 542,700 | 452,487 | (358,227) | 636,960 |
| m 0 |
DI O |
4I | O (D CD |
O (D Ot |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (D CO (D |
CD (O (D |
||||||||||
| lD | 4l | ID | ID | ||||||||
| m | 0 | OI CO |
CO | ||||||||
| OI | |||||||||||
| DI | |||||||||||
| ID0t | CO | CO | |||||||||
| CI | |||||||||||
| l3 8 0 |
CII0 OI |
4( | |||||||||
| N | |||||||||||
| m | |||||||||||
| m m |
CV o |
O | O | ||||||||
| Ct(3 | CD CO |
Ot CO |
|||||||||
| 4l | |||||||||||
| I- | D t- |
CV O Ol |
O | ||||||||
| MI-Z CII- |
00 m C 00 |
Ol olO OI |
4l | O Dt I(O |
O Dt CO |
||||||
| III | |||||||||||
| Ct | |||||||||||
| CI | |||||||||||
| D (D 0 |
OI CVO Ol |
4l | CO O CO |
CO O CO CO |
|||||||
| + | Dt | ||||||||||
| Dt | |||||||||||
| CIZ | Ct It" |
||||||||||
| 00 0I-Z0 CI0 |
CI UJDZI-z0 O V)I-Z UJ |
UI | m C CtG |
Ol O Ol |
4l | ID O |
ID O |
O PI |
|||
| Kl | |||||||||||
| UJ | m | ||||||||||
| 0 | I-c( M |
O LLI CI |
Dt 'O C C Ct |
(0 CI |
|||||||
| Cl | |||||||||||
| Xl | |||||||||||
| O0 V)z V)I- Kl ZI- |
OZ z UJZI-0I- N UJI-0z |
UI CI CI UJ |
8 (A lft Ol (DCID Ilt (0C |
E Ct0 tDD (0 N0t 0 C t0 Ol l3 C |
Cl lD Ct C(0 tfl S Ot |
fD Ct g (0 'at Ot Im |
(0 ID Zlt0 N S (0 C m 0 |